To evaluate the application of Ha-ras mRNA antisense oligonucleotide therapy for liver tumors, we examined the frequency and types of mutation in codon 61 of the Ha-ras oncogene in preneoplastic lesions and hepatocellular carcinomas induced by N-nitrosomorpholine (NNM) in rats. Thirtyseven percent of preneoplastic lesions and 50% of hepatocellular carcinomas contained mutations, mostly CAA-CTA and CAA-AAA transversions. We also investigated the effects on NNM-induced lesions of an antisense oligonucleotide directed against a point mutation (CAA-CTA) in codon 61 of Ha-ras mRNA. In this experiment, Sprague-Dawley rats were given free access to water containing NNM for 8 weeks and received twice-weekly i.p. injections of a mutated Ha-ras antisense oligonucleotide with a 5Ј phosphorothioate linkage or a sense oligonucleotide in oligonucleotide-liposome complexes. At week 16, rats that had received the mutated Ha-ras antisense oligonucleotides had significantly fewer and smaller preneoplastic lesions positive for glutathione-S-transferase, placental type, and had smaller hepatocellular carcinomas than rats that had received the sense oligonucleotide. Mean cellular fluorescence in the liver was found to increase with higher doses of mutated, fluorescein-isothiocyanate-labeled antisense or sense oligonucleotides. Moreover, mutated Haras antisense oligonucleotide decreased the expression of mutated Ha-ras mRNA (CAA-CTA). Our findings indicate that mutated Ha-ras antisense oligonucleotide significantly inhibits hepatocarcinogenesis in rats and could be an effective therapy against liver tumors. Int. J. Cancer 72:815-820, 1997.
Wiley-Liss, Inc.Point mutations in genes of the ras family, Ha-ras, K-ras and N-ras, have been detected in many human tumors (Bos, 1988;Tomono et al., 1996). In contrast with ras proto-oncogenes, which are expressed by all cells, ras oncogenes possess point mutations in the sequence encoding the active site, the GTP/GDP binding domains, of the ras proteins, most frequently at codons 12, 13 and 61. Even though their frequency in human tumors is estimated to be 20-30% (Bos, 1988), evidence suggests that mutated ras genes are directly involved in cell proliferation and tumorigenicity. In an attempt to improve cancer therapy, mutated ras genes in neoplastic cells have been blocked by antisense techniques. For example, short, modified antisense oligonucleotides directed against Ha-ras point mutations have been reported to induce in vitro selective cleavage of mRNA and to inhibit the proliferation of T24 cells (Saison-Behmoaras et al., 1991). Furthermore, antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles have been found to inhibit specifically cell proliferation and tumorigenicity in mutated Ha-ras-mediated bladder carcinoma in nude mice (Schwab et al., 1994).Antisense oligonucleotides are short sequences that have been used to suppress the expression of oncogenes and growth factors (Calabretta, 1991;Hélène, 1991). In theory, hybridization of the antisense oligonucleotide and the...